Top Markets
#1 DogBull DogBull +107.63%
#2 ADO Protocol ADO Protocol +51.91%
#3 Siacoin Siacoin +50.76%
#4 The Bitcoin Bull The Bitcoin Bull +44.24%
#5 MarsCoin MarsCoin +41.20%
#6 Ontology Gas Ontology Gas +23.42%
#7 Nockchain Nockchain +20.36%
#8 Apertum Apertum +20.22%
#9 UnifAI Network UnifAI Network +18.93%
#10 Falcon Finance Falcon Finance +16.52%
Coin of the day
DogBull DogBull
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Classificação em ações #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Preço da ação
$0.63963115
Última sincronização: 2026-08-26
Valor de mercado
$339.16M
Variação (1 dia)
0.00%
Variação (1 ano)
-35.23%
País
CN
Negociar Jiangsu Recbio Technology Co., Ltd. (2179)

Categoria

Healthcare
Margem Operacional de Jiangsu Recbio Technology Co., Ltd. (2179)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Jiangsu Recbio Technology Co., Ltd., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Jiangsu Recbio Technology Co., Ltd. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.